- Adherence is a critical issue to address in patients who are prescribed metformin.
- Sulfonylureas are still recommended as the standard initial option for addition to metformin.
- Treatment algorithms reflect the complexity of treatment decisions but offer consistent guidance on a stepped/progressive approach to blood glucose control.
Empagliflozin indications extended
Empagliflozin is now TGA-approved for reducing cardiovascular deaths in patients with type 2 diabetes with established cardiovascular disease.
What is the evidence, and what does this mean in clinical practice?
MedicineWise News: Type 2 diabetes – when metformin is not enough
Sulfonylureas are the usual add-on treatment when metformin is no longer sufficient, but are they the best? Review the evidence on efficacy, safety and outcomes for second-line type 2 diabetes treatments.
NPS RADAR: Pharmacological therapies in Australia for type 2 diabetes
Metabolic syndrome and diabetes: how much blame does sugar deserve?
An increasing number of journal articles and media stories are highlighting the potential role of dietary sugar, and particularly added fructose, as a major contributor to ill health, from cardiovascular disease to type 2 diabetes to metabolic syndrome.
Australian Prescriber: Encouraging adherence to long‑term medication
Aust Prescr 2017;40:147-501
Patients should be asked about adherence at every consultation.
Learn more about:
- using a collaborative communication style
- using the patient’s own expressions and responding to their cues
- how to normalise non-adherence
- using open questions and more specific probes.
Episode 6 – Encouraging adherence to long-term medication, with Prof Tim Usherwood
Dr Janine Rowse interviews Professor Tim Usherwood about the different types of medication non-adherence and his practical recommendations for better identification in the primary care setting.
Consolidate your knowledge about COPD, brush up on current guidelines and practices and earn CPD points through our learning activities.